VYGRライブシグナル | Getagraph.comで利益を最大化

売る 108137 min ago

@ $7.28

発行日: 14 2月 2024 @ 23:30

リターン: 8.24%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: -1.38 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Stats
本日の出来高	136 192
平均出来高	646 708
時価総額	427.89M
EPS	$0 ( 2024-02-28 )
次の収益日	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.65
ATR14	$0.0120 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferguson Toby	Buy	105 000	Common Stock
2024-04-02	Swartz Robin	Sell	1 357	Common Stock
2024-04-02	Sandrock Alfred	Sell	12 115	Common Stock
2024-03-25	Ferguson Toby	Buy	210 000	Stock Option (Right to Buy)
2024-03-25	Ferguson Toby	Buy	0

INSIDER POWER
44.43
Last 94 transactions
Buy: 7 546 876 \| Sell: 3 757 926

ボリューム相関

長: 0.10 (neutral)

短: -0.51 (weak negative)

Signal:(58.663) Neutral

Voyager Therapeutics Inc 相関

10 最も正の相関
DYNT	0.929
DGLY	0.909
CRNC	0.909
ATNX	0.905
GFAI	0.905
LIVE	0.897
FTFT	0.896
ECOR	0.896
CFRX	0.889
APRE	0.886

10 最も負の相関
MTEX	-0.862
ZENV	-0.859
VERA	-0.852
GRIN	-0.848
GRPH	-0.843
DSPC	-0.835
JAN	-0.832
RIVN	-0.831
LAWS	-0.827
VERX	-0.826

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Voyager Therapeutics Inc 相関 - 通貨/商品

-0.12
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.08
( neutral )

-0.62
( weak negative )

-0.05
( neutral )

Voyager Therapeutics Inc 財務諸表

Annual	2023
収益:	$250.01M
総利益:	$245.57M (98.22 %)
EPS:	$3.08

FY	2023
収益:	$250.01M
総利益:	$245.57M (98.22 %)
EPS:	$3.08

FY	2022
収益:	$40.91M
総利益:	$34.72M (84.87 %)
EPS:	$-1.210

FY	2021
収益:	$37.42M
総利益:	$0.00 (0.00 %)
EPS:	$-1.890

Financial Reports:

No articles found.

Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.